ALX Oncology Holdings Inc (ALXO) stock
ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.97−0.03 (-3.47%)
Close on Nov 18, 2026Market cap $134.14MP/E –Yield –
ALX Oncology total assets
Total assets on the balance sheet at the end of each period.
ALX Oncology's total assets was $160.82M at Jun 30, 2026. For fiscal 2025 it was $59.05M, down 60.0% from the year before. The highest annual figure on record is $436.05M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.05M | -60.0% |
| FY2024 | Dec 31, 2024 | $147.78M | -39.1% |
| FY2023 | Dec 31, 2023 | $242.55M | -20.9% |
| FY2022 | Dec 31, 2022 | $306.49M | -19.4% |
| FY2021 | Dec 31, 2021 | $380.18M | -12.8% |
| FY2020 | Dec 31, 2020 | $436.05M | +3984.4% |
| FY2019 | Dec 31, 2019 | $10.68M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $160.82M | +68.7% |
| Q1 FY2026 | Mar 31, 2026 | $178.33M | +47.5% |
| Q4 FY2025 | Dec 31, 2025 | $59.05M | -60.0% |
| Q3 FY2025 | Sep 30, 2025 | $82.72M | -55.5% |
| Q2 FY2025 | Jun 30, 2025 | $95.32M | -55.6% |
| Q1 FY2025 | Mar 31, 2025 | $120.90M | -43.1% |
| Q4 FY2024 | Dec 31, 2024 | $147.78M | -39.1% |
| Q3 FY2024 | Sep 30, 2024 | $185.72M | -15.6% |
| Q2 FY2024 | Jun 30, 2024 | $214.62M | -12.7% |
| Q1 FY2024 | Mar 31, 2024 | $212.65M | -23.5% |
| Q4 FY2023 | Dec 31, 2023 | $242.55M | -20.9% |
| Q3 FY2023 | Sep 30, 2023 | $220.11M | -30.7% |
| Q2 FY2023 | Jun 30, 2023 | $245.93M | -28.9% |
| Q1 FY2023 | Mar 31, 2023 | $278.14M | -23.5% |
| Q4 FY2022 | Dec 31, 2022 | $306.49M | -19.4% |
| Q3 FY2022 | Sep 30, 2022 | $317.69M | -20.5% |
| Q2 FY2022 | Jun 30, 2022 | $346.02M | -17.9% |
| Q1 FY2022 | Mar 31, 2022 | $363.68M | -16.0% |
| Q4 FY2021 | Dec 31, 2021 | $380.18M | -12.8% |
| Q3 FY2021 | Sep 30, 2021 | $399.73M | +52.3% |
| Q2 FY2021 | Jun 30, 2021 | $421.29M | +308.6% |
| Q1 FY2021 | Mar 31, 2021 | $432.91M | +3955.0% |
| Q4 FY2020 | Dec 31, 2020 | $436.05M | – |
| Q3 FY2020 | Sep 30, 2020 | $262.45M | – |
| Q2 FY2020 | Jun 30, 2020 | $103.11M | – |
| Q4 FY2019 | Dec 31, 2019 | $10.68M | – |
See a number that looks wrong?